|
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
|
|
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
|
|
Kahn, Josephine D; Miller, Peter G; Silver, Alexander J et al. (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095-1105
|
|
Tothova, Zuzana; Krill-Burger, John M; Popova, Katerina D et al. (2017) Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell 21:547-555.e8
|
|
Ajore, Ram; Raiser, David; McConkey, Marie et al. (2017) Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol Med 9:498-507
|
|
Krönke, Jan; Fink, Emma C; Hollenbach, Paul W et al. (2015) Lenalidomide induces ubiquitination and degradation of CK1? in del(5q) MDS. Nature 523:183-188
|
|
Yamazaki, Jumpei; Jelinek, Jaroslav; Lu, Yue et al. (2015) TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res 75:2833-43
|
|
Malouf, Gabriel G; Zhang, Jianping; Yuan, Ying et al. (2015) Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9:32-43
|
|
Fink, Emma C; Ebert, Benjamin L (2015) The novel mechanism of lenalidomide activity. Blood 126:2366-9
|
|
Lindsley, R Coleman; Mar, Brenton G; Mazzola, Emanuele et al. (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367-76
|
Showing the most recent 10 out of 80 publications
